Methodology
How the WeighScore is graded
Every provider is scored 0–100 across six weighted dimensions, then mapped to a letter grade. The same rubric runs against every provider — 6 factors, one formula, no exceptions. Here is exactly what we measure and how much it counts.
Cost value
25%Normalized price per month for an equivalent maintenance dose — sticker price, plus how it moves after any intro period. Hidden step-ups cost points.
Dose & formulation
20%Breadth of molecules (semaglutide, tirzepatide), titration flexibility, and route options (injection, oral, sublingual).
Clinical oversight
20%Provider verification confidence, prescriber model, and how care is supervised and escalated.
Labs & monitoring
15%Whether baseline labs, ongoing check-ins, and side-effect monitoring are included or bolt-on.
Fulfillment
12%Pharmacy sourcing transparency, shipping reliability, and cold-chain handling.
Contract terms
8%Cancellation friction, refund posture, auto-renewal honesty, and lock-in.
The arithmetic
WeighScore = the six factor scores multiplied by the weights above and added together. That is the whole formula. Every review page prints all six factor scores, so you can run the multiplication yourself and get the number in the grade tile — no factor is withheld, and the headline is never adjusted afterwards by hand.
When the FDA has written to a provider
Where the U.S. Food and Drug Administration has an active warning letter on file against a company we list, Clinical oversight is capped at 55 — one rule, the same number, applied to every such provider rather than a figure chosen company by company. That factor is defined above as provider verification confidence and how care is supervised, and a federal enforcement letter is direct evidence about exactly that. The remaining five factors are untouched and the WeighScore follows from the six as it always does. The letter itself is disclosed, with its date and a link to the FDA's own database, on every page where we list that provider.
The grade scale
A (93+), A− (90–92), B+ (87–89), B (83–86), B− (80–82), C+ (77–79), C (below 77). A grade is a relative read on today's market, not a safety rating.
What a commercial relationship can and cannot move
It cannot move the WeighScore. Assume any provider we list may compensate us. Every provider is marked against the identical rubric, the score is computed from the factors rather than typed in, and a weak provider grades low regardless.
What it can move is board position. Where a provider sits in a list is the thing our funding moves; the mark beside its name is not. We would rather print that than claim an independence we do not have — the mechanics are set out on our disclosure. Because of it, a provider scoring higher can sit lower on a board, and both numbers are printed on the row so you can see when it happens.
It cannot move the write-up either. A commercial relationship does not soften a review: an unflattering finding about a paying provider stays in, and where the evidence behind a claim is thin we say so — including for the providers we earn on. Every factor mark is printed on the row, so the reading is auditable. See our disclosure.
Provider facts come from each provider's public disclosures and the WLR provider matrix at the time of grading; they change often. This is consumer research, not medical advice.